Table 1 Clinical data
Patient demographics | |||||
|---|---|---|---|---|---|
Total number of patients | 13 | ||||
Male: Female | 7:6 | ||||
Median Age at Diagnosis in years (range) | 48 (39–71) | ||||
Median Age at R-2CdA treatment (range) | 59 (40–76) | ||||
Histology | |||||
Chronic lymphocytic leukemia/small | 9 | ||||
Lymphocytic lymphoma (CLL/SLL) | |||||
Waldenstrom’s Macroglobulinemia (WM) | 3 | ||||
Follicular lymphoma Grade I/II | 1 | ||||
Stage | |||||
Rai Stage IV | 6/8 | ||||
Ann Arbor (AA) Stage IV | 4/4 | ||||
Not determined | 1 | ||||
Prior therapy | |||||
Previously treated | 12 | ||||
Median number of prior regimens (range) | 3 (2–7) | ||||
Response | |||||
Total response rate (RR) (number/percent) | 10/13 (77%) | ||||
Complete response (CR) | 7/13 (54%) | ||||
Partial response (PR) | 3/13 (23%) | ||||
Progressive disease (PD) | 3/13 (23%) | ||||
Median duration of response (range) | 34 months (8-118+) | ||||
Common toxicity | Grade | ||||
Total % | 1 | 2 | 3 | 4 | |
Anemia | 8 (62%) | 6 | 1 | 1 | |
Thrombocytopenia | 8 (62%) | 5 | 1 | 2 | |
Neutropenia | 7 (54%) | 2 | 3 | 2 | |
Fatigue | 7 (54%) | 2 | 3 | 2 | |
Weight loss | 5 (38%) | 3 | 2 | ||